FDA Actions Against Celltex, Regeneron “Stifle Innovation,” Gov. Rick Perry Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The governor of Texas criticized FDA’s policies on use of autologous adult stem cells; the agency says stem cells used to treat patients are drug products.
You may also be interested in...
Permanent Vaccine Facility Should Be On Standby For Future Pandemics, Moncef Slaoui Says
Operation Warp Speed confirmed the necessity of having a facility on hand to develop and manufacture a vaccine for the next crisis, the outgoing advisor says.
FDA’s COVID-19 Pandemic Plan Calls For Ongoing Clinical Trial Innovation
Broader use of adaptive trial designs and master protocols, checklist-based application review, and enhancement of real-world monitoring of products are among the recommendations of US FDA's COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) report, an effort months in making based on interviews with agency management, staff, and outside stakeholders.
US FDA To Lose Another COVID-19 Response Leader With Anand Shah’s Resignation
Shah, deputy commissioner for medical and scientific affairs, has been overseeing FDA’s COVID-19 Pandemic Recovery and Preparedness Plan. His departure the week of 20 January follows that of FDA Chief Counsel Amy Amin, whose resignation led to dueling appointments to temporarily fill her post.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: